Pharmacopsychiatry 53 (2): 51 - 59, 2020 doi: 10.1055 / a-1046 - 1044 Key Points Neuroleptic malignant syndrome develops infrequently in patients taking neuroleptic or other drugs that decrease dopaminergic transmission.